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Abstract
Chronically increased echogenicity on renal ultrasound is a sensitive early finding of chronic 
kidney disease that can be detected before manifestation of other symptoms. Increased 
echogenicity, however, is not specific for a certain etiology of chronic kidney disease. Here, we 
performed whole exome sequencing in 79 consanguineous or familial cases of suspected 
nephronophthisis in order to determine the underlying molecular disease cause. In 50 cases, there 
was a causative mutation in a known monogenic disease gene. In 32 of these cases whole exome 
sequencing confirmed the diagnosis of a nephronophthisis-related ciliopathy. In 8 cases it revealed 
the diagnosis of a renal tubulopathy. The remaining 10 cases were identified as Alport syndrome 
(4), autosomal-recessive polycystic kidney disease (2), congenital anomalies of the kidney and 
urinary tract (3), and APECED syndrome (1). In 5 families, in whom mutations in known 
monogenic genes were excluded, we applied homozygosity mapping for variant filtering, and 
identified 5 novel candidate genes (RBM48, FAM186B, PIAS1, INCENP, and RCOR1) for renal 
ciliopathies. Thus, whole exome sequencing allows the detection of the causative mutation in 2/3 
of affected individuals, thereby presenting the etiologic diagnosis and allows identification of 
novel candidate genes.
Keywords
chronic kidney disease; pediatric nephrology; genetic kidney disease; whole exome sequencing; 
mutation analysis; monogenic diseases; increased renal echogenicity; nephronophthisis
INTRODUCTION
Renal ultrasound imaging (RUS) represents a simple and broadly accessible tool for the non-
invasive early diagnosis of chronic kidney disease (CKD) in children and young adults. 
Often abnormal findings on RUS are detectable years before the kidney function deteriorates 
and before other symptoms develop. A typical abnormal finding in early stages of CKD is 
chronically increased echogenicity on RUS. It is frequently accompanied by loss of cortico-
medullary differentiation and renal cysts. Increased echogenicity is easily detected as a 
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degree of echogenicity that is equal to or more pronounced than the echogenicity of the liver. 
Unfortunately, chronically increased echogenicity is not specific to certain types of kidney 
disease1–3. Particularly in early stages, in which other symptoms are not yet present, a 
correct diagnosis can be challenging. In these cases, whole exome sequencing (WES) 
provides a novel means of establishing an etiologic diagnosis. By revealing the causative 
monogenic mutation, it provides affected individuals and their families with an unequivocal, 
early diagnosis1. As a result, a targeted therapeutic regimen can be initiated early if 
available.
Chronically increased echogenicity on RUS is often found in the early stages of 
nephronophthisis-related ciliopathies (NPHP-RC). NPHP-RC represent a group of cystic 
and fibrotic kidney diseases with an autosomal recessive mode of inheritance that typically 
progress to end-stage renal failure within the first three decades of life4, 5. Nephronophthisis 
can present as isolated renal disease (MIM #613550), or together with extrarenal symptoms 
such as retinal degeneration (Senior Loken syndrome MIM #266900), cerebellar vermis 
hypoplasia (Joubert syndrome MIM #213300), and hepatic fibrosis. The renal manifestation 
ranges from severe, early onset cystic kidney disease6 to slowly progressive, fibrotic 
remodeling of the kidney with CKD starting in adolescence7. Interestingly, the genotype-
phenotype correlation in NPHP-RC is dependent on the gene and the specific mutation 
involved, which can both give rise to a broad phenotypic disease spectrum. NPHP-RC are a 
very heterogeneous disease group as by now, mutations in more than 90 genes have been 
identified as causative for renal ciliopathies in humans4. Mutations in some of these genes 
are very rare, accounting for only two8, or three9 families worldwide. WES with direct 
inspection of the coding regions of these genes therefore represents the most rational and 
currently, most cost-effective approach for mutation analysis in these patients1, 10–12. So far, 
no more than 13 ciliopathy genes have been systematically studied in a larger patient 
cohort13, 14.
Here, we performed WES combined with homozygosity mapping in an international cohort 
of 79 families with pediatric onset of CKD and suspected nephronophthisis based on renal 
ultrasound presentation with chronically increased echogenicity, loss of cortico-medullary 
differentiation, and/ or ≥2 cysts. All individuals were born of consanguineous union, or 
represented familial cases of CKD, and were therefore at high risk for recessive, monogenic 
diseases. In summary, we were able to identify a mutation in a known monogenic disease 
gene in 50 families (63.3%). In 32 of these families (64%) WES identified mutations in 
NPHP-RC genes as the molecular disease cause, and confirmed the suspected clinical 
diagnosis. However, in 18 families (36%) we discovered a molecular diagnosis of a 
monogenic kidney disease that was not NPHP-RC, specifically renal tubulopathies (n=8, 
16%), Alport syndrome (n=4, 8%), congenital anomalies of the kidney and urinary tract 
(CAKUT) (n=3, 6%), autosomal recessive polycystic kidney disease (ARPKD) (n=2, 4%), 
and autoimmune nephropathy (APECED syndrome) (n=1, 2%). In 5 consanguineous 
families, in whom we excluded mutations in known monogenic disease genes, we identified 
5 novel candidate genes for NPHP-RC (RBM48, FAM168B, PIAS1, INCENP, and 
RCOR1).
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RESULTS
WES identifies the molecular disease cause in 63% of cases
We performed WES in 79 families with suspected NPHP-RC based on renal ultrasound 
criteria (chronically increased echogenicity, loss of cortico-medullary differentiation, and/or 
≥2 renal cysts). In 50/79 families (63.3%) we identified a mutation in a gene that is known to 
cause monogenic renal disease when mutated (Fig. 1A, Suppl. Table 1 / 2).
NPHP-RC account for 64% of molecularly diagnosed individuals
32 of the 50 families with established molecular diagnosis after WES (64.0%) harbored a 
mutation in a known NPHP-RC gene (Fig. 1B). Of the 90 genes that are known to cause 
renal ciliopathies when mutated which were systematically analyzed in this study, mutations 
in 18 genes contributed to this result. Mutations in the genes NPHP3, NPHP4, and NPHP5 
accounted for the majority of NPHP-RC cases (Table 1, Suppl. Table 1/2). In addition to 
mutations in NPHP-RC genes, we detected causative mutations in monogenic genes of renal 
tubulopathies (8/50), Alport syndrome (4/50), CAKUT (3/50), and ARPKD (2/50). 
Furthermore, we established the molecular diagnosis of APECED (autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy) in one previously undiagnosed 
individual (Fig. 1B, Table 1, Suppl. Table 1/2). In 10 individuals, the molecular diagnosis 
after WES was different from the previous clinical diagnosis. In particular, in one case of 
previously undiagnosed nephropathic cystinosis the molecular finding changed the 
therapeutic regimen (Suppl. Table 1/2).
Mutations in more than one recessive disease gene can be present in consanguineous 
families
In one example of a highly inbred family (412 Mb of cumulative homozygosity) we 
identified homozygous mutations in 7 known monogenic disease genes. 4 of them are 
known to cause diseases with renal involvement (Suppl. Table 3). The affected child showed 
a complex phenotype suggestive of a renal ciliopathy including Caroli's disease with massive 
cystic dilation of intrahepatic bile ducts, CKD that progressed to end-stage renal failure 
within the 3rd year of life, post axial polydactyly, nystagmus, and red cone dystrophy. In 
addition to chronically increased echogenicity as the classical symptom of NPHP-RC, the 
child showed congenital hydronephrosis due to uretero-pelvic junction obstruction (UPJO) 
that required corrective surgery, as well as renal tubular acidosis type 4. (Suppl. Table 3). An 
older brother, from whom no DNA sample was available for mutation analysis, deceased at 
15 months of age due to end-stage renal and liver disease. Additionally, he showed post axial 
polydactyly and blindness at 5 months of age due to progressive retinal dystrophy. A 
younger brother presented with Caroli's disease and retinitis pigmentosa. Interestingly, no 
polydactyly was present, and the renal function was preserved at 3 years of age. The right 
kidney showed mild pelvicalyceal dilation.
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The percentage of molecularly solved cases in consanguineous families and familial cases 
of suspected NPHP-RC is comparable (~63%)
When performing WES in 79 families with suspected nephronophthisis based on renal 
ultrasound imaging with childhood-onset chronically increased renal echogenicity and/or ≥2 
renal cysts, we detected a causative mutation in a known monogenic disease gene in 38 of 60 
consanguineous families (63.3%) (Fig. 2). As postulated15, 16 in the vast majority of 
consanguineous families the causative mutation was present in the homozygous state (37 of 
38 families (97.4%)) (Fig. 2). The only exception was a family in whom we identified a 
single heterozygous mutation in the dominant gene HNF1ß as causative. In 12 of 19 non-
consanguineous families with 2 or more affected children (63.2%) we identified a causative 
monogenic mutation, showing a comparable percentage of molecularly solved cases in both 
cohorts. However, as expected in non-consanguineous families16 only in 3 of 12 families 
(25.0%) the disease-causing mutation was present in the homozygous state. The remaining 9 
of 12 families (75.0%) harbored two compound heterozygous disease-causing mutations 
(Fig. 2).
Identification of 5 novel candidate genes for NPHP-RC
By applying homozygous peak regions as a filter for WES data, we identified 5 novel 
candidate genes for monogenic, recessive NPHP-RC (Table 2). In these 5 consanguineous 
families we had excluded mutations in known monogenic disease genes with renal 
phenotypes through evaluation and direct inspection of the WES data. The 5 novel candidate 
genes (RBM48, FAM168B, PIAS1, INCENP, and RCOR) represented the most deleterious 
alleles within the homozygous regions (Suppl. Fig 2) after variant filtering as outlined in 
Suppl. Fig 1. In the example of family A2621 with 181 Mb of cumulative homozygosity 
(Suppl. Table 4), we started with 482,406 variants from normal reference sequence. 
Excluding common variants (minor allele frequency >1% in healthy control cohorts), 
synonymous variants, and heterozygous variants reduced the number to 1,699. Considering 
only variants that were positioned within homozygous peak regions reduced the number of 
remaining variants by 11 fold to 156. Exclusion of artifacts by direct inspection of the 
sequence alignment, left us with 3 potentially disease causing variants in this family (Suppl. 
Table 4). Subsequently, these 3 variants were ranked based on their predicted likelihood to 
be deleterious for the function of the encoded protein following the criteria as outlined in 
Suppl. Fig. 1. At the end of the filtering process the gene INCENP (Inner centromere 
protein) represented the strongest remaining variant in this family. All mutations in novel 
candidate genes were confirmed by Sanger sequencing in original patient DNA, and 
segregated with the affected status.
24 families (30.4%) remained without a molecular diagnosis after WES. In these families, 
no convincing biallelic variants in known monogenic genes, or candidate genes were 
identified that segregated with the affected status.
DISCUSSION
We performed WES combined with homozygosity mapping in 79 consanguineous or 
familial cases of childhood onset chronically increased renal echogenicity or the presence of 
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≥2 cysts on renal ultrasound. Based on renal ultrasound presentation, clinical presentation 
with childhood-onset of disease, and if available renal histology, a nephronophthisis-related 
ciliopathy (NPHP-RC) was suspected as the primary disease cause. We show that in this 
patient cohort, WES allows detecting the specific causative mutation in about 2/3 of affected 
individuals, thereby presenting the etiologic diagnosis. In addition, we identified 5 potential 
novel renal ciliopathy genes in consanguineous families in whom mutations in 90 known 
monogenic NPHP-RC genes had been excluded.
Chronically increased echogenicity on renal ultrasound represents a sensitive diagnostic 
criterion for early stages of CKD in children and young adults. Typically, this results in the 
suspected diagnosis of nephronophthisis or related ciliopathies. However, we and others1–3 
have shown that other kidney diseases can phenocopy the presentation of NPHP-RC on renal 
ultrasound. Here, we study 79 consanguineous or familial cases with suspected NPHP-RC 
based on renal ultrasound presentation with childhood-onset increased renal echogenicity 
and/or more than one cyst, and perform WES in order to determine the percentage in which 
NPHP-RC and various other monogenic, recessive kidney diseases contribute to this 
phenotypic spectrum (Figure 2). As a second aspect, we aimed to systematically examine all 
90 genes that are known monogenic, recessive causes of NPHP-RC or other CKD that can 
phenocopy the presentation of NPHP-RC in a large cohort of affected individuals. So far, 
this has not been done for more than 13 renal ciliopathy genes13, 14 at a time. As we 
identified the disease-causing mutation in ~ 2/3 (50/79) of individuals with increased 
echogenicity on RUS, our data shows that WES is an efficient tool for molecular diagnostics 
in this patient cohort. WES provides affected individuals and their families with an 
unequivocal diagnosis that avoids unnecessary diagnostic and therapeutic interventions. 
WES is a non-invasive diagnostic tool with little risk, and recently, the cost has dropped to a 
level that makes it accessible to a broader group of affected individuals in a clinical rather 
than a research setting. Considering the genetic heterogeneity of NPHP-RC, WES is the only 
available technique that can reliably establish the correct molecular diagnosis. The use of 
targeted sequencing panels as utilized for other disease entities in clinical genetics is 
technically not feasible and/or not economical for such a large number of potentially 
causative genes. However, WES yields a large number of variants from normal reference 
sequence, most of which are functionally irrelevant. Therefore an efficient strategy for 
variant filtering is indispensable for the work with WES data. In addition, variant calling 
should follow an indication-driven strategy: After thorough clinical evaluation, a subset of 
potentially causative genes should be defined prior to WES, and the evaluation should 
primarily focus on variants in these genes. For example in a patient with increased 
echogenicity and/or ≥2 cysts on renal ultrasound, primarily variants in the ~90 monogenic 
causes of renal ciliopathies, and genes that can phenocopy NPHP-RC, should be taken into 
consideration.
In our cohort, WES molecularly confirmed the clinically suspected diagnosis of NPHP-RC 
in 64% of cases. However, 18/50 individuals (36%) harbored a mutation in a gene that 
causes a monogenic kidney disease different from NPHP-RC. As already described in a 
smaller cohort1, the majority of these cases (8/18) were diagnosed as renal tubulopathies. In 
addition, we identified 4 individuals with Alport syndrome, 3 individuals with mutations in 
CAKUT genes, 2 individuals with ARPKD, and 1 individual with autoimmune nephropathy 
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in the context of APECED syndrome. In 10 of these 18 cases the molecular diagnosis 
differed from the initial clinical diagnosis. We therefore suggest that WES helps to 
distinguish between NPHP-RC and other kidney diseases that phenocopy the presentation of 
NPHP-RC on renal ultrasound. This can be particularly advantageous in very early stages of 
disease progression in which additional characteristic symptoms might not yet be present, as 
well as for very rare genetic syndromes. This observation underlines an additional benefit of 
WES: The genetic diagnostic is not restricted to a limited subset of monogenic diseases that 
were already suspected based on the clinical presentation, but a broader spectrum of 
monogenic causes can be taken into consideration. In addition, the very high rate of 
detecting a causative mutation in genes that are known to be mutated in renal disorders with 
increased echogenicity, confirms that increased renal echogenicity, even if performed in 
numerous centers worldwide, is a reproducible and reliable criterion for non-invasive 
diagnostic in pediatric kidney disease. Interestingly, the percentage of molecularly diagnosed 
individuals was not considerably different in consanguineous families as compared to 
outbred sibling cases. We therefore suggest that the relevance of our findings reaches beyond 
consanguineous cases.
As we and others have shown10, 12, 17 combining WES and homozygosity mapping in 
consanguineous families represents a powerful tool for the identification of novel human 
disease genes. We applied this technique in 5 families in whom mutations in known human 
disease genes had been excluded, and we identified RBM48, FAM168B, PIAS1, INCENP, 
and RCOR1 as novel candidate genes for renal ciliopathies. So far, mutation analysis has not 
yielded additional families with mutations in these genes. However, this rarity is not 
unexpected as for the majority of recently identified NPHP-RC genes less than 10 families 
with mutations have been described worldwide9–12, 18–20 At this point, additional functional 
evidence to proof the pathogenicity of these mutations is lacking. Further genetic and 
experimental evidence in the future will help to determine whether mutations in these newly 
identified candidate genes are indeed disease-causing in humans with renal ciliopathies.
24 of 79 families in our cohort (30.4%) remained without a molecular diagnosis after WES. 
This is not unexpected as in recessive monogenic diseases only about 85% of all causative 
mutations are located within the coding sequence or the adjacent splice sites21, 22. The 
remaining 15% however, are complex deletion-insertion variants, copy-number variants, or 
reside within a promotor and other intronic region. As none of these variants can be detected 
by WES, this technical limitation explains why some cases cannot be solved by WES. 
Furthermore, WES might miss a subset of causative variants due to low coverage in the 
respective target region. Considering the fact that about 20% of all individuals with NPHP-
RC harbor a homozygous deletion in the NPHP1 gene, the percentage of solved cases in this 
study had been even higher than the reported 63% if these cases were included. As it has 
been postulated that only 85% of recessive mutations can be technically detected with 
currently available techniques22, we show that in the targeted patient cohort virtually all 
cases with detectable recessive mutations are molecularly solved after WES.
We here present WES as a rapid and reliable tool for molecular diagnostics in 
consanguineous individuals or familial cases with clinically suspected NPHP-RC based on 
renal ultrasound that allows establishing an etiologic diagnosis in ~2/3 of affected 
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individuals. This represents a major advance in a diagnostic finding that is frequently 
interpreted as “medical renal disease” rather than leading to an etiologic diagnosis.
MATERIALS AND METHODS
Human subjects
The study was approved by the institutional review board (IRB) of the University of 
Michigan and Boston Children's Hospital. After obtaining informed consent, clinical data, 
and pedigree information, DNA samples were collected from individuals with suspected 
nephronophthisis based on clinical findings, renal ultrasound criteria, and if present, renal 
histology. Subjects were either of consanguineous families, or sibling cases with multiple 
affected children in one family. 107 individuals from 82 families were included in the study. 
4 individuals (from 3 families) were excluded for technical reasons, leading to a final cohort 
of 103 individuals from 79 families. 60 families were consanguineous singlets, and 19 
families were non-consanguineous familial cases with more than one affected child (16 
families with 2 affected children, 2 families with 3 affected children, and 1 family with 5 
affected children). In all families a homozygous deletion in the NPHP1 gene had been 
excluded prior to study inclusion. This was necessary as homozygous deletions in the 
NPHP1 gene represent the most frequently observed mutation in individuals with 
nephronophthisis, but cannot be detected by whole-exome sequencing.
Linkage analysis
For genome-wide homozygosity mapping the GeneChip® Human Mapping 250k Sty Array 
from Affymetrix was used. Non-parametric LOD scores were calculated using a modified 
version of the program GENEHUNTER2.123, 24 through stepwise use of a sliding window 
with sets of 110 SNPs and the program ALLEGRO25 in order to identify regions of 
homozygosity as described15, 26 using a disease allele frequency of 0.0001 and Caucasian 
marker allele frequencies. The genetic mapping was based on multipoint analysis. A non-
parametric LOD score of 2 was applied as the threshold for relevant homozygous peak 
regions, and a nonparametric LOD cut-off of 0.5 as threshold for linkage in sibling cases.
Whole Human Exome Capture, Next Gen Sequencing, Sequence Alignment, and Variant 
Calling
Genomic DNA was isolated from blood lymphocytes and subjected to whole exome capture 
using a customized Agilent SureSelect All Exome Kit v2.0 (Agilent Technologies, Santa 
Clara, CA, USA) according to manufacturer's protocol. The library was sequenced on an 
Illumina HighSeq™ sequencing platform. Image analysis and base calling were generated 
by the Illumina pipeline using default parameters. Sequence reads were mapped to the 
human reference genome assembly (NCBI build 3/hg19) using CLC Genomics 
Workbench™ (version 6.5.2) software (CLC bio, Aarhus, Denmark). In consanguineous 
cases, only variants with a common allele frequency of more than 80% were called for 
further evaluation in order to identify homozygous variants. Trimmed sequence reads were 
mapped to the human reference genome (hg19) using the Map Reads to Reference program 
with the following settings: mismatch cost = 2, insertion cost = 3, deletion cost =3, length 
fraction = 0.5, similarity fraction = 0.9 and map to nonspecific reads = “randomly”. The 
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non-specific reads were then ignored for count and coverage. All variants with a minimum 
coverage of 2 were used. The variations in the samples were called using probabilistic 
variant detection using CLC bio. All the called variants were then annotated and evaluated 
using mutation calling criteria as outlined in Suppl. Fig. 1.
Variant Annotation and Evaluation
After alignment to the human reference genome, variants were filtered as previously 
described1, 27, and as summarized in Suppl. Fig. 1. The ranking and calling of alleles as 
disease-causing mutations follows accepted standards in molecular diagnostics28–31, and 
with regards to the composition of our cohort, we applied criteria that are even stricter than 
the ones typically used in the field. In the first step variants with minor allele frequencies 
>1% in the dbSNP (version 135) or the 1,000 Genomes (1,094 subjects of various 
ethnicities; May, 2011 data release) databases were excluded. In the second step only 
homozygous and biallelic variants (in non-consanguineous cases) were kept, whereas single 
heterozygous variants were excluded from the further evaluation. Subsequently, in step 3 
synonymous variants and intronic variants that were not located within splice site regions 
were excluded. In step 4 genetic mapping data (homozygosity mapping in consanguineous 
families and linkage analysis in sibling cases) was applied for variant filtering15. In the final 
step, remaining variants were ranked based on their probable impact on the function of the 
encoded protein. We considered only mutations as disease-causing that full-filled the 
following criteria: a) protein-truncating, or b) previously reported as disease-causing in 
individuals with a similar phenotype (HGMD biobase), or c) missense mutations were only 
included if they affected highly conserved amino acid residues (conserved in orthologues 
below vertebrate evolution) and were not reported with a minor variant frequency >0.5% in 
healthy control individuals, and were predicted to be deleterious for the protein function 
(PolyPhen-2 score32 >0.7). Variants that were present in the homozygous state in any 
publicly available control cohort were excluded. Mutation calling was performed by 
geneticists/cell biologists, who had knowledge of the clinical phenotypes and pedigree 
structure, as well as experience with homozygosity mapping and exome evaluation. 
Remaining variants were confirmed in original patient DNA by Sanger sequencing as 
previously described33. Whenever parental DNA was available, segregation analysis was 
performed.
In a second evaluation process, variants in all 90 genes that are known monogenic, recessive 
causes of NPHP-RC or other CKD that can phenocopy the presentation of NPHP-RC were 
systematically evaluated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Relative number of cases molecularly diagnosed by WES in 79 families with child-hood 
onset chronically increased echogenicity or ≥2 cysts on renal ultrasound
A) We performed whole exome sequencing in 79 consanguineous or sibling cases with 
increased echogenicity and/or ≥2 cysts on renal ultrasound. In 50 families (63.3%) we 
identified a mutation in a known monogenic disease gene as causative. In 5 families (6.3%) 
we identified a mutation in a novel candidate gene for NPHP-RC, and 24 families (30.4%) 
remained without a molecular diagnosis after WES.
B) Fractional contribution of different disease entities to the molecular diagnosis of 50 
families in whom a causative mutation in a known monogenic disease gene was detected. 
(See Table 1 for the underlying monogenic causes in each disease group.)
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Figure 2. Algorithm for molecular diagnostics in consanguineous or familial cases of suspected 
nephronophthisis based on renal ultrasound presentation
Of 79 families with childhood-onset increased renal echogenicity and/or ≥ 2 cysts on RUS, 
60 individuals were born of consanguineous unions, and 19 families were non-
consanguineous with two or more affected children. In 63.3% of consanguineous families, 
we identified a mutation in a known monogenic disease gene as causative. The majority of 
these mutations were, as postulated, present in the homozygous state. In 63.2% of familial 
cases, we identified a causative mutation in a recessive, monogenic disease gene. 3/4 of 
these mutations were compound heterozygous.
a
 In one consanguineous family a single heterozygous mutation in the dominant gene 
HNF1ß was identified as the molecular disease cause.
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Table 1
Diagnostic groups and distribution among specific genes with causative recessive mutations in 50 families 
with increased echogenicity and/or ≥ 2 cysts on renal ultrasound in whom the disease-causing mutation was 
detected by WES.
Disease group Patients within the disease group Gene with causative mutation (disease, OMIM#a)
NPHP-RC 32/50 (64.0%)
2/50 (4.0%) NPHP1 (Nephronophthisis type, juvenile, #256100)
3/50 (6.0%) NPHP3 (Nephronophthisis type 3, #604387)
5/50 (10 %) NPHP4 (Nephronophthisis type 4, #606966)
3/50 (6.0%) IQCB1 (Senior-Loken syndrome type 5, #609254)
1/50 (2.0%) CEP290 (Senior-Loken syndrome 6, #610189)
2/50 (4.0%) SDCCAG8 (Senior-Loken syndrome type 7, #613615)
1/50 (2.0%) TMEM67 (Nephronophthisis 11, #613550)
2/50 (4.0%) TTC21B (Nephronophthisis 12, #613820)
2/50 (4.0%) WDR19 (Nephronophthisis 13, #614377)
3/50 (6.0%) ANKS6 (Nephronophthisis 16, #615382)
1/50 (2.0%) TMEM138 (Joubert syndrome 16, #614465)
1/50 (2.0%) TMEM231 (Joubert syndrome 20, #614970)
1/50 (2.0%) ARL6 (Bardet-Biedl syndrome 3, #600151)
1/50 (2.0%) BBS4 (Bardet-Biedl syndrome 4, #615982)
1/50 (2.0%) MKKS (Bardet-Biedl syndrome 6, #605231)
1/50 (2.0%) BBS12 (Bardet-Biedl syndrome 12, #615989)
1/50 (2.0%) DYNC2H1 (Short-rib thoracic dysplasia 3, #613091)
1/50 (2.0%) IFT43 (Cranioectodermal dysplasia 3, #614099)
Renal tubulopathies 8/50 (16.0%)
3/50 (6.0%) CLDN16 (Hypomagnesemia 3, renal, #248250)
2/50 (4.0%) CLCNKB (Bartter syndrome, type 3, #607364)
1/50 (2.0%) ATP6V0A4 (Renal tubular acidosis, distal, #602722)
1/50 (2.0%) BCS1L (Mitochondrial complex III deficiency, #124000)
1/50 (2.0%) CTNS (Cystinosis, nephropathic, #219800)
Alport syndrome 4/50 (8.0%)
2/50 (4.0%) COL4A3 (Alport syndrome, #203780)
1/50 (2.0%) COL4A4 (Alport syndrome, #203780)
1/50 (2.0%) COL4A5 (Alport syndrome, #301050)
CAKUT 3/50 (6.0%)
2/50 (4.0%) HNF1b (Renal cysts and diabetes syndrome, #137920)
1/50 (2.0%) FREM2 (Fraser syndrome, #219000)
Autosomal recessive polycystic 
kidney disease 2/50 (4.0%) PKHD1 (Polycystic kidney and hepatic disease, #263200)
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Disease group Patients within the disease group Gene with causative mutation (disease, OMIM#a)
APECED 1/50 (2.0%) AIRE (Autoimmune polyendocrinopathy syndrome type I, #240300)
APECED, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy; CAKUT, congenital anomalies of the kidney and urinary tract; 
NPHP-RC, nephronophthisis related ciliopathies
aOnline Mendelian Inheritance in Man (OMIM), http://www.omim.org;
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